The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.

In recent news, the FDA granted Fast Track designation to remlifanserin (ACP-204; Acadia Pharmaceuticals), an investigational selective serotonin 5-HT2A receptor inverse agonist, for the treatment of ...

The FDA has granted fast track designation to Scholar Rock’s apitegromab (Isembyld), a muscle-targeting therapy recently approved for the treatment of spinal muscular atrophy (SMA), for patients ...

Xenon Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for azetukalner (XEN1101) as adjunctive treatment for focal seizures in adults with epilepsy, based on ...

Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes] ...

A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in ...

"Unmet Needs and Mechanisms Behind Newer Agitation Therapies" takes up what still remains unmet in agitation care, and the biology behind a newer treatment option.

EPOCH is a single-center, prospective, randomized, open-label, blinded-endpoint (PROBE) trial being conducted at National Taiwan University Hospital. The study was registered in March 2024, and ...

Levacetylleucine (AQNEURSA) is approved for the treatment of ataxia in adults and pediatric patients with ataxia-telangiectasia weighing at least 15 kg, in addition to its existing indication for ...

The 2026 AHA/ASA adult stroke rehabilitation guideline updates the 2016 framework, addressing evidence-based recovery ...